MA50045A - Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci - Google Patents
Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ciInfo
- Publication number
- MA50045A MA50045A MA050045A MA50045A MA50045A MA 50045 A MA50045 A MA 50045A MA 050045 A MA050045 A MA 050045A MA 50045 A MA50045 A MA 50045A MA 50045 A MA50045 A MA 50045A
- Authority
- MA
- Morocco
- Prior art keywords
- preparation
- methods
- same
- spirocyclic compounds
- spirocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762551714P | 2017-08-29 | 2017-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50045A true MA50045A (fr) | 2020-07-08 |
Family
ID=65526036
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050045A MA50045A (fr) | 2017-08-29 | 2018-08-28 | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11161856B2 (fr) |
| EP (1) | EP3675848B1 (fr) |
| JP (1) | JP7177825B2 (fr) |
| KR (1) | KR20200046053A (fr) |
| CN (1) | CN111032034B (fr) |
| AU (1) | AU2018326497A1 (fr) |
| BR (1) | BR112020003946A2 (fr) |
| CA (1) | CA3072926A1 (fr) |
| CL (1) | CL2020000463A1 (fr) |
| CO (1) | CO2020001715A2 (fr) |
| CR (1) | CR20200088A (fr) |
| DO (1) | DOP2020000040A (fr) |
| EA (1) | EA202090296A1 (fr) |
| EC (1) | ECSP20013332A (fr) |
| ES (1) | ES2914363T3 (fr) |
| IL (1) | IL272578A (fr) |
| JO (1) | JOP20200022A1 (fr) |
| MA (1) | MA50045A (fr) |
| MX (1) | MX2020002254A (fr) |
| PE (1) | PE20200665A1 (fr) |
| PH (1) | PH12020500371A1 (fr) |
| RU (1) | RU2020107039A (fr) |
| SG (1) | SG11202000984YA (fr) |
| WO (1) | WO2019046330A1 (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104159581B (zh) | 2012-01-06 | 2017-09-01 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| US10030020B2 (en) | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JP7042804B2 (ja) | 2016-09-19 | 2022-03-28 | ルンドベック ラ ホーヤ リサーチ センター，インク． | ピペラジンカルバメート、及びその製造と使用の方法 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| KR20200046053A (ko) | 2017-08-29 | 2020-05-06 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 |
| PE20211385A1 (es) * | 2018-05-15 | 2021-07-27 | Lundbeck La Jolla Research Center Inc | Inhibidores de magl |
| CN111505410B (zh) * | 2020-04-02 | 2022-07-29 | 矽力杰半导体技术(杭州)有限公司 | 调光模式检测电路、方法和无调光检测电路及照明系统 |
| AU2021259496A1 (en) | 2020-04-21 | 2022-11-10 | H. Lundbeck A/S | Synthesis of a monoacylglycerol lipase inhibitor |
| TW202229255A (zh) | 2020-11-13 | 2022-08-01 | 丹麥商Ｈ 朗德貝克公司 | Magl抑制劑 |
| US20230357190A1 (en) * | 2022-05-04 | 2023-11-09 | H. Lundbeck A/S | Crystalline forms of a magl inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002070523A1 (fr) * | 2001-03-07 | 2002-09-12 | Pfizer Products Inc. | Modulateurs de l'activite du recepteur de la chimiokine |
| US20110172230A1 (en) * | 2006-08-23 | 2011-07-14 | Takahiro Ishii | Urea compound or salt thereof |
| EP2257549A1 (fr) | 2008-03-05 | 2010-12-08 | Targacept Inc. | Amides de diazabicycloalcanes sélectives d'un sous-type de récepteur d'acétylcholine nicotinique |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| EP2491038B1 (fr) | 2009-10-23 | 2016-04-06 | Janssen Pharmaceutica N.V. | Octahydropyrrolo[3,4-c]pyrroles disubstitués en tant que modulateurs de récepteur d'orexine |
| CA2791672A1 (fr) | 2010-03-04 | 2011-09-09 | Merck Sharp & Dohme Corp. | Modulateurs allosteriques positifs de mglur2 |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| EP2444084A1 (fr) | 2010-10-21 | 2012-04-25 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Utilisation d'inhibiteurs de PI3K pour le traitement de l'obésité |
| CN104159581B (zh) * | 2012-01-06 | 2017-09-01 | 阿比德治疗公司 | 氨基甲酸酯化合物及其制备和使用方法 |
| CA2878442A1 (fr) | 2012-09-25 | 2014-04-03 | F. Hoffmann-La Roche Ag | Derives du hexahydropyrrolo[3,4-c]pyrrole et composes similaires en tantqu'inhibiteurs de l'autotaxine (atx) et inhibiteurs de la production de l'acide lysophosphatidique (lpa) pour traiter des maladies renales |
| CA2917050A1 (fr) | 2013-07-03 | 2015-01-08 | Todd K. Jones | Composes de pyrrolo-pyrrole carbamate et composes organiques associes, compositions pharmaceutiques et leurs utilisations medicales |
| EP3271352B1 (fr) * | 2015-03-18 | 2021-05-12 | H. Lundbeck A/S | Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci |
| MX2018000929A (es) | 2015-07-31 | 2018-05-22 | Pfizer | Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl. |
| WO2017087854A1 (fr) * | 2015-11-20 | 2017-05-26 | Abide Therapeutics, Inc. | Composés de pyrazole, procédés de production et utilisation |
| US10030020B2 (en) | 2016-05-12 | 2018-07-24 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| MA50041A (fr) | 2017-08-29 | 2020-07-08 | Lundbeck La Jolla Research Center Inc | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci |
| KR20200046053A (ko) | 2017-08-29 | 2020-05-06 | 룬드벡 라 졸라 리서치 센터 인코포레이티드 | 스피로사이클 화합물 및 이를 제조하고 사용하는 방법 |
-
2018
- 2018-08-28 KR KR1020207007712A patent/KR20200046053A/ko unknown
- 2018-08-28 WO PCT/US2018/048388 patent/WO2019046330A1/fr unknown
- 2018-08-28 CN CN201880054296.1A patent/CN111032034B/zh active Active
- 2018-08-28 ES ES18852217T patent/ES2914363T3/es active Active
- 2018-08-28 BR BR112020003946-2A patent/BR112020003946A2/pt not_active Application Discontinuation
- 2018-08-28 JO JOP/2020/0022A patent/JOP20200022A1/ar unknown
- 2018-08-28 SG SG11202000984YA patent/SG11202000984YA/en unknown
- 2018-08-28 CR CR20200088A patent/CR20200088A/es unknown
- 2018-08-28 MA MA050045A patent/MA50045A/fr unknown
- 2018-08-28 AU AU2018326497A patent/AU2018326497A1/en not_active Abandoned
- 2018-08-28 US US16/642,713 patent/US11161856B2/en active Active
- 2018-08-28 EA EA202090296A patent/EA202090296A1/ru unknown
- 2018-08-28 EP EP18852217.1A patent/EP3675848B1/fr active Active
- 2018-08-28 PE PE2020000297A patent/PE20200665A1/es unknown
- 2018-08-28 CA CA3072926A patent/CA3072926A1/fr not_active Abandoned
- 2018-08-28 RU RU2020107039A patent/RU2020107039A/ru unknown
- 2018-08-28 JP JP2020512612A patent/JP7177825B2/ja active Active
- 2018-08-28 MX MX2020002254A patent/MX2020002254A/es unknown
-
2020
- 2020-02-10 IL IL272578A patent/IL272578A/en unknown
- 2020-02-14 CO CONC2020/0001715A patent/CO2020001715A2/es unknown
- 2020-02-21 EC ECSENADI202013332A patent/ECSP20013332A/es unknown
- 2020-02-21 DO DO2020000040A patent/DOP2020000040A/es unknown
- 2020-02-24 PH PH12020500371A patent/PH12020500371A1/en unknown
- 2020-02-25 CL CL2020000463A patent/CL2020000463A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RU2020107039A (ru) | 2021-09-30 |
| DOP2020000040A (es) | 2020-08-31 |
| CN111032034A (zh) | 2020-04-17 |
| CA3072926A1 (fr) | 2019-03-07 |
| EP3675848B1 (fr) | 2022-03-23 |
| US20210214375A1 (en) | 2021-07-15 |
| IL272578A (en) | 2020-03-31 |
| ECSP20013332A (es) | 2020-04-22 |
| SG11202000984YA (en) | 2020-03-30 |
| EP3675848A4 (fr) | 2021-03-10 |
| CL2020000463A1 (es) | 2020-07-10 |
| US11161856B2 (en) | 2021-11-02 |
| JP7177825B2 (ja) | 2022-11-24 |
| PH12020500371A1 (en) | 2020-12-07 |
| CR20200088A (es) | 2020-04-08 |
| WO2019046330A1 (fr) | 2019-03-07 |
| ES2914363T3 (es) | 2022-06-09 |
| EP3675848A1 (fr) | 2020-07-08 |
| JP2020532547A (ja) | 2020-11-12 |
| AU2018326497A1 (en) | 2020-02-20 |
| EA202090296A1 (ru) | 2020-08-03 |
| CN111032034B (zh) | 2023-05-02 |
| PE20200665A1 (es) | 2020-06-11 |
| JOP20200022A1 (ar) | 2020-02-02 |
| BR112020003946A2 (pt) | 2020-09-08 |
| CO2020001715A2 (es) | 2020-02-28 |
| MX2020002254A (es) | 2020-07-20 |
| KR20200046053A (ko) | 2020-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50045A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA50041A (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
| MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
| MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci | |
| MA46479A (fr) | Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène | |
| MA54252A (fr) | Composés de benzoxazépine oxazolidinone et leurs procédés d'utilisation | |
| MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
| MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
| MA52492A (fr) | Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés | |
| MA49752A (fr) | Procédés de préparation de composés de pyrrolidine | |
| MA50636A (fr) | Compositions et procédés pour inhiber l'activité d'arginase | |
| MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
| MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
| MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
| MA43364A (fr) | Composés d'alcènes tétrasubstitués et leur utilisation | |
| MA46791A (fr) | Composés et procédés pour réduire l'expression d'atxn3 | |
| MA45688A (fr) | Compositions et procédés de potentialisation d'agents antimicrobiens | |
| MA48797A (fr) | Variants de l'endonucléase cblb , compositions et procédés d'utilisation | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| MA44611A (fr) | Compositions de composés hydrophobes cristallisés et leurs procédés de préparation et d'utilisation | |
| MA49560A (fr) | Composés cétoniques bicycliques et leurs procédés d'utilisation | |
| MA39915B1 (fr) | Composés de pladiénolide pyridine et leurs procédés d'utilisation | |
| MA47167A (fr) | Composés pyrazolopyrimidine et leurs procédés d'utilisation | |
| MA46546A (fr) | Composés thérapeutiques et leurs procédés d'utilisation |